These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32988145)

  • 1. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
    Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
    [No Abstract]   [Full Text] [Related]  

  • 2. BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.
    Quan L; Lan X; Meng Y; Guo X; Guo Y; Zhao L; Chen X; Liu A
    Exp Hematol; 2018 Apr; 60():47-56.e1. PubMed ID: 29353075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
    Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
    Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
    Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
    Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
    Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
    Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
    Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
    J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes.
    Shokrgozar N; Dehghani M; Golmoghaddam H; Moghadam M; Rezaei N; Moayed V; Arandi N
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e388-e397. PubMed ID: 35098660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
    Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
    Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
    Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.
    Stühler V; Alemi B; Rausch S; Stenzl A; Schwab M; Schaeffeler E; Bedke J
    World J Urol; 2024 Jan; 42(1):53. PubMed ID: 38244072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
    Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection.
    Liu Z; Li S; Liu Y; Guo W; Bai O
    PLoS One; 2017; 12(6):e0180390. PubMed ID: 28662185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade.
    Grabmeier-Pfistershammer K; Stecher C; Zettl M; Rosskopf S; Rieger A; Zlabinger GJ; Steinberger P
    Clin Immunol; 2017 Oct; 183():167-173. PubMed ID: 28882621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.
    Zhao M; Wang L; Wang X; He J; Yu K; Li D
    Tumori; 2024 Aug; 110(4):227-240. PubMed ID: 38183180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
    Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
    Front Immunol; 2019; 10():835. PubMed ID: 31134049
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 19. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
    Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
    J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.